Data shows excretion of codeine in fingerprint sweat INBS’ System is viable option for non-invasive diagnostic testing NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing and screening solutions, today announced that it will present its Pharmacokinetic (“PK”) study data at the Association for Diagnostics and Laboratory Medicine (“ADLM”) 2025 Clinical Lab Expo, tak ...

Company Overview - Rich Sparkle Holdings Limited is a financial printing and corporate services provider specializing in high-quality financial print materials in Hong Kong [7] - The company's service portfolio includes listing documents, financial reports, fund documents, circulars, and announcements, along with advisory services such as internal control assessments and ESG performance evaluations [7] Initial Public Offering (IPO) Details - The company closed its initial public offering of 1,250,000 ordinary shares at a public offering price of $4.00 per share, resulting in total gross proceeds of $5 million before underwriting discounts and commissions [1] - The offering was conducted on a firm commitment basis, with Eddid Securities USA Inc. acting as the underwriter [3] - The ordinary shares commenced trading on the Nasdaq Capital Market under the ticker symbol "ANPA" on July 8, 2025 [2] Use of Proceeds - Proceeds from the offering will be allocated for incorporating generative AI features into service modules, establishing new branches and offices in the U.S., recruiting staff for expansion, forming strategic alliances, and general corporate purposes [1]

Core Insights - Zebra Technologies Corporation (ZBRA) is positioned to benefit from strong performance across its business segments, operational excellence, and strategic acquisitions, focusing on growth opportunities and long-term market positioning [1] Business Performance - The Enterprise Visibility & Mobility segment has seen an 8.1% year-over-year revenue increase in Q1 2025, driven by higher sales of mobile computing and data capture solutions, along with increased service and software sales [2] - The Asset Intelligence & Tracking segment experienced an 18.4% year-over-year sales increase in Q1 2025, supported by solid demand for printing solutions and RFID products [3] - For Q2 2025, the company anticipates net sales growth of 4-7% compared to the same quarter last year, reflecting overall business strength [3] Acquisition Strategy - Zebra Technologies acquired Photoneo in March 2025, enhancing its 3D machine vision solutions by integrating Photoneo's technology with its existing capabilities [4] - The acquisition of Matrox Imaging in June 2022 has allowed Zebra to strengthen its fixed industrial scanning and machine vision portfolio [5] Stock Performance and Shareholder Returns - ZBRA's stock has increased by 44.6% over the past three months, outperforming the industry average growth of 42% [8] - The company has repurchased shares worth $125 million in Q1 2025, compared to $47 million in Q1 2024, with a remaining buyback capacity of $721 million from a $1 billion program authorized in May 2022 [9] - Free cash flow for Q1 2025 reached $158 million, marking a 42.3% year-over-year increase, supporting shareholder-friendly policies [9] Earnings Estimates - The Zacks Consensus Estimate for ZBRA's 2025 earnings is $14.51 per share, reflecting a 7.3% year-over-year increase, while the estimate for 2026 earnings is $16.41 per share, indicating a 13.1% increase from the previous year [10]

Hong Kong, July 07, 2025 (GLOBE NEWSWIRE) -- Rich Sparkle Holdings Limited (NASDAQ: ANPA) (the “Company”), a financial printing and corporate services provider which specializes in designing and printing high quality financial print materials in Hong Kong, today announced the pricing of its initial public offering (“Offering”) of 1,250,000 ordinary shares at a public offering price of $4.00 per share. The ordinary shares have been approved for listing on the Nasdaq Capital Market and are expected to commenc ...

NEW YORK, July 7, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against 3D Systems Corporation ("3D Systems" or the "Company") (NYSE: DDD) and certain officers. The class action, filed in the United States District Court for the District of Delaware, and docketed under 25-cv-00734, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired 3D Systems securities between August 13, 2024 and May 12, 2025, b ...

An updated edition of the May 29, 2025 article.3D Printing, also known as additive manufacturing, is a cutting-edge process that transforms digital designs into physical objects by building them layer by layer with remarkable precision. Since its inception in the 1980s, the technology has evolved rapidly and revolutionized the way manufacturers design, create and produce. From customized prosthetics and mechanical components to architectural structures, food and intricate jewelry creations, 3D Printing has ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against 3D Systems Corporation for alleged violations of federal securities laws, urging affected investors to contact them before the August 12, 2025 deadline for lead plaintiff applications in a federal class action lawsuit [2][4]. Financial Performance - 3D Systems reported Q4 2024 non-GAAP earnings-per-share of -$0.19, missing consensus estimates by $0.08, with sales revenue of $111 million, a year-over-year decline of 3.4%, and a full-year 2024 sales total of $440.1 million, down 10% from the previous year [5]. - In Q1 2025, the company reported revenue of $94.5 million, an 8% year-over-year decline, and a net loss of $37 million, or $0.28 per share, which is more than double the $16 million loss reported in Q1 2024 [6]. Stock Price Reaction - Following the Q4 2024 results announcement, 3D Systems' stock price fell by $0.57, or 20.96%, closing at $2.15 per share [5]. - After the Q1 2025 results were released, the stock price dropped by $0.68, or 26.6%, to close at $1.87 per share [7]. Allegations of Misconduct - The complaint against 3D Systems alleges that the company and its executives made false or misleading statements regarding the impact of weakened customer spending and overstated the company's resilience in challenging market conditions [4]. - It is also claimed that updated milestone criteria in the United Partnership would negatively affect the revenue from the Regenerative Medicine Program, leading to materially false public statements [4].

Collaboration with French MedTech company, TISSIUM, has resulted in FDA approval for unique 3D-printed polymeric solution for repair of peripheral nerve damage3D Systems’ bioprinting system enabled production of a 3D-printed bioabsorbable medical device leveraging TISSIUM’s proprietary biomorphic programable polymers—a major industry milestone that sets new standard for high resolution elastomeric 3D-printed medical implantsBuilds on 3D Systems’ pioneering work to develop additive manufacturing solutions fo ...

Financial Performance & Growth - Protolabs achieved $504 million in revenue in 2023[6] - The company's Non-GAAP gross margin was 45% in 2023[6] - Adjusted EBITDA reached $83 million in 2023[6] - Protolabs Network revenue experienced a 69% year-over-year growth in constant currencies in 2023[60] - The company's revenue increased by 5% year-over-year, excluding Japan, in 2023[56] Customer Base & Manufacturing - Protolabs has served over 53,000 customer contacts[6,36] - The company has manufactured over 450 million parts to date[6] - Over 85% of Fortune 500 companies in target industries are served by Protolabs[36] - More than 90% of revenue comes from returning customers[44] Market & Outlook - Protolabs operates in a $100 billion+ market[8,14,18] - The company anticipates Q1 2024 revenue between $120 million and $128 million, representing a growth range of -5% to 2% year-over-year[73] - Non-GAAP EPS for Q1 2024 is projected to be between $0.26 and $0.34, indicating a year-over-year growth range of -12% to 15%[73]

With over 450 accounts across 24 countries, INBS continues to advance the evolution of drug screening technologyNEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, non-invasive drug screening solutions, today announced the success of its ongoing partnership with Spjotgard, an established distributor serving the Scandinavian market. The collaboration is accelerating the adoption of the Intell ...